A new study has raised concerns about the health risks associated with discontinuing GLP-1 medications, widely used for treating Type 2 diabetes and obesity. Researchers found that stopping these drugs can significantly increase the risk of heart attack, stroke, and even death.
The study, conducted by Washington University School of Medicine and published in BMJ Medicine, analyzed electronic health records of more than 333,000 adults with Type 2 diabetes over a three-year period. Many of the participants were using semaglutide-based treatments such as Ozempic.
Increased Cardiovascular Risk After Stopping Treatment
The findings revealed that patients who continued taking GLP-1 medications experienced an 18 percent reduction in cardiovascular risk over three years. However, even short interruptions in treatment had noticeable consequences.
Patients who stopped the medication for just six months saw their risk increase by 4 percent compared to those who continued treatment. A gap of two years led to a 22 percent higher risk of cardiovascular events, including heart attacks and strokes.
Researchers emphasized that the protective effects of GLP-1 drugs build gradually over time but can diminish quickly once treatment stops.
More Than Just Weight Loss
Experts note that GLP-1 medications provide benefits beyond weight loss. These drugs help lower cholesterol levels, reduce blood pressure, improve insulin sensitivity, and decrease inflammation. Together, these effects contribute to better heart health.
According to researchers, discontinuing the medication can reverse these benefits, leading to what they describe as a “metabolic whiplash,” where improvements rapidly decline once treatment ends.
High Dropout Rates Remain a Concern
Despite their benefits, a significant number of patients stop using GLP-1 drugs. Studies estimate discontinuation rates between 36 percent and 81 percent. The reasons include side effects such as nausea and vomiting, as well as limited access and high costs.
Experts stress that patients and healthcare providers should carefully consider long-term treatment plans when starting GLP-1 medications. These drugs are not designed for short-term use, and stopping them prematurely may carry serious health risks.
Future Outlook
Efforts are underway to address the challenges associated with GLP-1 treatments. Pharmaceutical companies are working on next-generation drugs that aim to deliver similar benefits with fewer side effects. At the same time, broader insurance coverage may improve access to these medications in the future.
The study highlights the importance of maintaining consistent treatment and suggests that stopping GLP-1 drugs should be approached with caution due to the potential impact on cardiovascular health.
